Showing results filtered by:
103 Results
Clinical research policies and standard procedure documents for NIAID microbiology and infectious diseases research
Last Reviewed: February 14, 2025
Listing of former Senior Investigators with the Laboratory of Infectious Diseases
Last Reviewed: August 19, 2024
Related Extramural SOP: Special Issues Requiring Council Review Present the following special issues to Council: Reinstatement of Research Aims. Applications for which the division is requesting to reinstate Specific Aims or research not recommended for support by the study section. Council does not review restorations of budget or years cut by the study section, but because of the budgetary
Last Reviewed: December 7, 2023
Policies and standard operating procedures (SOPs) related to NIAID Division of AIDS clinical research protocol and informed consent development.
Last Reviewed: December 11, 2024
GVIRF 2023 GVIRF 2023 Agenda GVIRF 2023 Presentations GVIRF 2021 GVIRF 2021 Agenda GVIRF 2021 Presentations GVIRF Publications (2014-2021) GVIRF 2021 Publication GVIRF 2018 Publication GVIRF 2016 Publication GVIRF 2014 Publication
Last Reviewed: October 5, 2023
Between GVIRF meetings, a series of webinars is held to address emerging vaccination and immunization research issues of interest. Past Webinars February 2024 New TB Vaccines for Adults and Adolescents, Progress, Prospects, and Perspectives, February 22, 2024 September 2023 Vaccine Adjuvants for Global Health, Webinar Agenda Vaccine Adjuvants for Global Health, Webinar Video Vaccine Adjuvants for
Last Reviewed: October 4, 2024
DAIDS Timing of Consent and Reconsent
https://www.niaid.nih.gov/sites/default/files/TimingOfConsentReconsent.pdf
Last Reviewed: November 23, 2021
Fauci-Presentation-Zika-Hearing-5-12-16
https://www.niaid.nih.gov/sites/default/files/Fauci-Presentation-Zika-Hearing-5-12-16_v1.pdf
NIAID's leadership includes Jeanne Marrazzo, M.D., M.P.H., Sarah W. Read, M.D., M.H.S., Jill R. Harper, Ph.D., H. Clifford Lane, M.D., Carl W. Dieffenbach, Ph.D., Daniel Rotrosen, M.D., Emily Erbelding, M.D., M.P.H., Kelly Poe, Ph.D., Steven M. Holland, M.D., and Ted C. Pierson, Ph.D.
Last Reviewed: April 28, 2025
Turning the Corner on the AIDS Pandemic: Focusing the Science-Driven HIV Research Enterprise Sept. 20, 2017 Video: Archived Presentation: Refining NIH’s HIV Research Enterprise September 5, 2017 Video: Archived Presentation: Refining the Clinical Trials Units for NIAID Networks August 4, 2017 Video: Archived Presentation: Dieffenbach Explains HIV Network Refinement June 1, 2017 Video: You Can
Last Reviewed: January 18, 2019
Leprosy (Hansen's Disease) is a chronic infectious disease that primarily affects the peripheral nerves, skin, upper respiratory tract, eyes, and nasal mucosa (lining of the nose). The disease is caused by a bacillus (rod-shaped) bacterium known as Mycobacterium leprae.
Last Reviewed: September 15, 2015
Kim J. Hasenkrug, Ph.D., is a special volunteer in the Laboratory of Neurological Infections and Immunity. He is the former Chief of the Retroviral Immunology Section.
Last Reviewed: January 14, 2025
Senior Leadership for NIAID's Vaccine Research Center (VRC)
Last Reviewed: February 25, 2025
COVID-19
Last Reviewed: March 6, 2024
Published: July 3, 2024
The purpose of this study is to find out whether two drugs, carfilzomib (Kyprolis®),and belatacept (Nulojix®), can make these kidney transplant candidates less sensitized, and make it easier and quicker to find a kidney donor for them.
The purpose of this study is to find out whether two drugs, daratumumab (Darzalex®), and belatacept (Nulojix®), can make these kidney transplant candidates less sensitized, and make it easier and quicker to find a kidney donor for them.
With the 2023 NIAID Three-minute Talk (TmT) Competition and NIH Postbac Poster Day just around the corner, now is a great time to examine your skills as a presenter and strengthen any areas that need improvement. Check out these strategies for designing great presentations that are memorable and engaging.
Published: April 3, 2023
NIAID is cohosting an Advances in Aging, Immunity, and Chronic Inflammatory Diseases workshop on May 9 and 10, 2023. The workshop will be hybrid, meaning there are options to attend in person or virtually.
Published: April 5, 2023
The HIV clinical trials network sites have made tremendous contributions to NIH’s scientific priorities by offering direct access to and consultation with populations most affected by HIV globally, and by delivering high-quality clinical research with strong connections to trusted community outreach platforms. Future networks will need to maintain core strengths of current models while expanding capacity in areas vital to further scientific progress. These include operations that inform pandemic responses and extending our reach within communities impacted by HIV, including populations historically underrepresented in clinical research.
Published: September 3, 2024
NIAID fellows now have two new representatives to the NIH Fellows Committee, better known as FelCom. Read on to learn more about NIAID’s new FelCom reps, Vaccine Research Center postdoc Sila Ataca and Rocky Mountain Laboratories postdoc Arthur Wickenhagen, Ph.D., and the experiences that led them to their new roles.
Published: July 3, 2023
GVIRF 2021 Presentations Introduction to GVIRF (B. Fenton Hall, NIAID) Keynote Speakers Vaccinology in the context of pandemic preparedness: The COVID-19 experience (Anthony Fauci, NIAID) The lessons of COVID-19 for vaccine development (Bill Gates, BMGF) Innovating from research to impact at scale: the role of the Gavi Alliance (Anuradha Gupta, Gavi) Research for equity (Soumya Swaminathan, WHO)
Last Reviewed: April 21, 2022
Background information about the Director of the NIAID Division of Allergy, Immunology, and Transplantation, Daniel Rotrosen, M.D.
Last Reviewed: May 8, 2018
The primary objective is to evaluate the safety and feasibility of administering CART BCMA + huCART-19 following lymphodepletion, including determination of optimal tolerated regimen (OTR) and/or recommended phase 2 regimen, according to the incidence of dose limiting toxicity (DLT) in highly sensitized patients awaiting kidney transplant.
The purpose of this study is to strengthen our ability to accurately diagnose allergies and understand cellular, humoral, genetic components and physiological changes in allergic disease.